Alumis Inc. (ALMS)
NASDAQ: ALMS · Real-Time Price · USD
8.82
+0.19 (2.20%)
Dec 20, 2024, 4:00 PM EST - Market closed
Alumis Employees
As of December 31, 2023, Alumis had 109 total employees, including 107 full-time and 2 part-time employees.
Employees
109
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,190,587
Market Cap
479.87M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 109 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Auna S.A. | 14,958 |
| Ginkgo Bioworks Holdings | 1,218 |
| MeiraGTx Holdings | 425 |
| Sangamo Therapeutics | 405 |
| MaxCyte | 143 |
| AnaptysBio | 117 |
| Theravance Biopharma | 99 |
| Terns Pharmaceuticals | 66 |
ALMS News
- 5 weeks ago - Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements - GlobeNewsWire
- 2 months ago - Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside - Benzinga
- 2 months ago - Alumis: Could This Broken Immunology IPO Become The Next Amgen? - Seeking Alpha
- 3 months ago - Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study - GlobeNewsWire
- 3 months ago - Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases - Seeking Alpha
- 3 months ago - Alumis to Participate in Upcoming September Investor Conferences - GlobeNewsWire
- 4 months ago - Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements - GlobeNewsWire
- 5 months ago - Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis - GlobeNewsWire